# The Safety and Effectiveness of Taneasy and Actein in COPD Patients

> **NCT06688292** · PHASE4 · COMPLETED · sponsor: **Bun Yao Biotechnology Co., Ltd** · enrollment: 42 (actual)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** Taneasy 600mg granules
- **DRUG:** Actein effervescent 600mg

## Key facts

- **NCT ID:** NCT06688292
- **Lead sponsor:** Bun Yao Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06688292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06688292, "The Safety and Effectiveness of Taneasy and Actein in COPD Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06688292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*